Comparative Pharmacology
Head-to-head clinical analysis: CUROSURF versus INFASURF PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CUROSURF versus INFASURF PRESERVATIVE FREE.
CUROSURF vs INFASURF PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CUROSURF is a natural porcine lung surfactant containing phospholipids and surfactant-associated proteins B and C. It reduces surface tension in the alveoli, preventing alveolar collapse at end-expiration and improving lung compliance and gas exchange.
Infasurf (calfactant) is a natural bovine lung extract containing phospholipids (primarily dipalmitoylphosphatidylcholine, DPPC) and surfactant-associated proteins B and C. It reduces alveolar surface tension, preventing end-expiratory collapse and stabilizing alveoli, thereby improving lung compliance and gas exchange.
Curosurf is administered intratracheally as a single dose of 100-200 mg/kg (1.25-2.5 mL/kg) of birth weight, given as soon as possible after birth. Repeat doses of 100 mg/kg (1.25 mL/kg) may be given at 12-hour intervals up to a total of 3 doses if needed.
Not applicable; Infasurf Preservative Free is an intratracheal suspension indicated only for neonatal respiratory distress syndrome (RDS).
None Documented
None Documented
The terminal elimination half-life is approximately 24-48 hours in preterm infants, reflecting slow clearance from the lungs; clinical effects on lung function can be seen within minutes.
Terminal half-life in preterm infants: 10-17 hours; clearance correlates with lung maturation and surfactant recycling.
The primary route of elimination is via alveolar macrophages and clearance from the lungs; renal and biliary excretion are negligible as the drug is a surfactant administered directly to the lungs.
Primarily cleared by alveolar macrophages and lung surfactant turnover; minimal renal or biliary excretion (<1%).
Category C
Category C
Pulmonary Surfactant
Pulmonary Surfactant